ClinicalTrials.gg
CompletedNCT04327388Updated Sep 24, 2025Results posted

Sarilumab COVID-19

A Phase 3 interventional study of Sarilumab SAR153191 and Placebo in Corona Virus Infection, sponsored by Sanofi. Completed at 47 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Coronavirus Infections with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Coronavirus Infections · France.

Enrollment
14th of 45
420 · median 228
Started
2020
with 77 others
Phase 3
12 of 89
2 open now
Registered
13th of 89
by date

Among the 89 studies in Coronavirus Infections with a site in France, this one is the 14th largest by enrollment of the 45 interventional ones that give a count, is one of 78 that started in 2020, is one of 12 in phase 3, and was the 13th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

4 of the 89 studies in Coronavirus Infections with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Coronavirus Infections with a site in France, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19).

Secondary Objectives:

  • Evaluate the 28-day survival rate.
  • Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity.
  • Evaluate changes in the National Early Warning Score 2.
  • Evaluate the duration of predefined symptoms and signs (if applicable).
  • Evaluate the duration of supplemental oxygen dependency (if applicable).
  • Evaluate the incidence of new mechanical ventilation use during the study.
  • Evaluate the duration of new mechanical ventilation use during the Study.
  • Evaluate the proportion of participants requiring rescue medication during the 28-day period.
  • Evaluate need for admission into intensive care unit.
  • Evaluate duration of hospitalization (days).
  • The secondary safety objectives of the study were to evaluate the safety of sarilumab through hospitalization (up to Day 29 if participant was still hospitalized) compared to the control arm as assessed by incidence of:

    • Serious adverse events.
    • Major or opportunistic bacterial or fungal infections in participants with grade 4 neutropenia.
    • Grade greater than or equal to (>=) 2 infusion related reactions.
    • Grade >=2 hypersensitivity reactions.
    • Increase in alanine transaminase (ALT) >=3X upper limit of normal (ULN) (for participants with normal baseline) or greater than 3X ULN AND at least 2-fold increase from baseline value (for participants with abnormal baseline).
    • Major or opportunistic bacterial or fungal infections.
Read the detailed description

An individual participant would complete the study approximately 60 days from screening to follow-up on day 60 ±7 days.

03

Conditions studied

  • Corona Virus Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must be >=18 years of age. Participants must be hospitalized for less than or equal to 7 days with evidence of pneumonia and have one of the following disease categories: severe disease or critical disease.

Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection.

Exclusion criteria

Exclusion criteria:

Unlikely to survive after 48 hours from screening or unlikely to remain at the site beyond 48 hours. Participants with multi organ dysfunction or requiring extracorporeal life support or renal replacement therapy were excluded.

Presence of neutropenia less than 2000/cubic millimeter (mmˆ3), or ALT greater than 5X , less than 50,000/mmˆ3.

Prior therapies. Use of systemic chronic for non-COVID-19 related condition. Known or suspected history of tuberculosis. Suspected or known active systemic bacterial or fungal infections.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    Sarilumab 200 mg

    Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]): * Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and * Increase/recurrence of fever or * Increase/no change in fraction of inspired oxygen (FiO2) requirement or * Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction.

    Drug: Sarilumab SAR153191

  • Experimental
    Sarilumab 400 mg

    Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]): * Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and * Increase/recurrence of fever or * Increase/no change in FiO2 requirement or * Required vasopressors, ECMO or development of multi-organ dysfunction.

    Drug: Sarilumab SAR153191

  • Placebo comparator
    Placebo

    Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]): * Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and * Increase/recurrence of fever or * Increase/no change in FiO2 requirement or * Required vasopressors, ECMO or development of multi-organ dysfunction.

    Drug: Placebo

Interventions

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

    Also known as: REGN88, Kevzara®

  • DrugPlacebo

    Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points

    Time to improvement of greater than or equal (\>=) 2 points in clinical status assessment was defined as time (in days) from first dose of study drug to the time of first occurrence of improvement of \>=2 points in clinical status of participants assessed using 7-point ordinal scale (calculated as: Date of first occurrence/episode of the event - date of first dose + 1). Seven-point ordinal scale for clinical assessment ranges from 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score = less severity. Kaplan-Meier method was used for analysis.

    Time frame: Baseline to Day 29

Secondary outcomes

  1. Percentage of Participants Who Were Alive at Day 29

    Percentage of participants who were alive at Day 29 were reported in this outcome measure.

    Time frame: Day 29

  2. Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29

    Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity. Percentage of participants With \>=1 point improvement in clinical status from Baseline at Days 4, 7, 15, 21, and 29 (assessed using the 7-point ordinal scale) were reported.

    Time frame: Baseline, Days 4, 7, 15, 21, and 29

  3. Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score

    Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity.

    Time frame: Baseline, Days 4, 7, 15, 21, and 29

  4. Time to Resolution of Fever

    Resolution of fever was defined as body temperature less than or equal to (\<=) 36.6 degree Celsius (°C) (axilla), or \<=37.2°C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics/until discharge, whichever was sooner. Time to resolution of fever (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever) - date of first dose + 1. Kaplan-Meier method was used for estimation.

    Time frame: Baseline to Day 29

  5. Time to Resolution of Fever and Improvement in Oxygenation

    Time to resolution of fever was defined as body temperature \<=36.6°C (axilla), or \<=37.2 °C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, whichever was sooner. Improvement in oxygenation was defined as oxygen saturation (SpO2)/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours, or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to resolution of fever and improvement in oxygenation (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever and improvement in oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.

    Time frame: Baseline to Day 29

  6. Number of Days With Fever

    Fever was defined as body temperature greater than (\>) 37.4°C (axilla), or \>38.0 °C (oral), or \>38.4°C (rectal or tympanic) based on maximum value observed during a 24-hour period. Number of days with fever were reported. Least square (LS) mean and standard error (SE) were estimated using the analysis of covariance (ANCOVA) model with treatment group and randomization strata as fixed effects.

    Time frame: Baseline to Day 29

  7. Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29

    NEWS2: used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. Percentage of participants in following clinical risk categories were reported: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).

    Time frame: Baseline, Days 4, 7, 15, 21, and 29

  8. Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours

    Time to NEWS2 \<2 and maintained for 24 hours: time (in days) from 1st dose of study drug until 1st occurrence of NEWS score of \<2 (maintained for 24 hours); calculated as: date of 1st occurrence/episode of event (NEWS score of \<2) - date of 1st dose + 1. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (score of 0 or 1 was allocated) and level of consciousness (score of 0 or 3 was allocated), where 0=normal health condition to 3=worst health condition; higher score=more severity. All scores were summed to get an aggregate score which ranged from 0 to 19, with higher scores=more severity/higher risk. Kaplan-Meier method was used for analysis.

    Time frame: Baseline to Day 29

  9. Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2

    The NEWS2 was used to standardize the assessment of acute-illness severity, track the clinical condition of participants, and to alert clinical teams to participant deterioration. NEWS2 score is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. LS means and SE were estimated using ANCOVA model with treatment group and randomization strata as fixed effects, and baseline NEWS2 score as a covariate.

    Time frame: Baseline, Days 4, 7, 15, 21, and 29

  10. Time-to-improvement in Oxygenation

    Time-to-improvement in oxygenation was defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to improvement in oxygenation was calculated as: date of first occurrence/episode of the event (oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.

    Time frame: Baseline to Day 29

  11. Percentage of Participants Alive Off Supplemental Oxygen at Day 29

    Supplemental oxygen was defined as oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device.

    Time frame: Day 29

  12. Percentage of Days With Hypoxemia

    Hypoxemia (low level of oxygen in the blood) was defined as SpO2 \<93% on room air, or required supplemental oxygen, or mechanical ventilatory support. Days meeting the criteria for hypoxemia since the first study dose were counted and the percentage of days with hypoxemia were calculated as:100\*number of days with the hypoxemia divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

    Time frame: Baseline to Day 29

  13. Percentage of Days With Supplemental Oxygen Use

    Supplemental oxygen (oxygen therapy) was defined as oxygen administration using oxygen delivery device (e.g. nasal cannula, simple face mask, non-rebreather mask, high flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, extracorporeal life support, etc.). Days meeting the criteria for supplemental oxygen use since the first study dose were counted and the percentage of days with supplemental oxygen use were calculated as:100\*number of days with the supplemental oxygen use divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29) . LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

    Time frame: Baseline to Day 29

  14. Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute

    Resting respiratory rate was measured in terms of number of breaths per minute (bpm) while a person is at rest. Only the days with respiratory rate \>24 breath per minute since the first dose were counted and percentage of days with respiratory rate \> 24 bpm were calculated as:100\*number of days with respiratory rate \>24 bpm divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

    Time frame: Baseline to Day 29

  15. Time to Oxygen Saturation >= 94% on Room Air

    Time to oxygen saturation \>=94% on room air was defined as the time (in days) from first dose of study drug until the time of first occurrence of oxygen saturation \>=94% and it was calculated as: Date of first occurrence/episode of the event (oxygen saturation \>=94%) - date of first dose + 1.Kaplan-Meier method was used for estimation.

    Time frame: Baseline to Day 29

  16. Mean Number of Ventilator Free Days

    Mean number of ventilator free days in participants were reported.

    Time frame: Baseline to Day 29

  17. Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula

    Percentage of participants With initiation of mechanical ventilation or non-invasive ventilation, or use of high flow nasal cannula were reported in this outcome measure.

    Time frame: Baseline to Day 29

  18. Percentage of Participants Who Required Rescue Medication

    Rescue medications were defined as the immunosuppressive (methylprednisolone, dexamethasone and prednisone) therapies. During the course of the study, participant who required rescue therapy was based on the judgement of the study physician.

    Time frame: Baseline to Day 28

  19. Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study

    Percentage of participants who needed ICU care until Day 29 were reported for those not in an ICU at baseline.

    Time frame: Baseline to Day 29

  20. Number of Days of Hospitalization Among Survivors (Alive Participants)

    Number of days of hospitalization among alive participants were counted at Day 60 since the first dose. LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

    Time frame: At Day 60

  21. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Treatment-emergent AEs (TEAEs) were the AEs that developed or worsened or became serious during the TEAE period (from the time of first dose of study drug to the last dose of study drug + 60 days). SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.

    Time frame: Baseline up to 60 days

  22. Number of Participants With Major or Opportunistic Bacterial or Fungal Infections

    Major or opportunistic bacterial or fungal infections was considered as an adverse event of special interest (AESI: defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).

    Time frame: Baseline up to 60 days

  23. Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection

    Grade 4 neutropenia was defined as participants with absolute neutrophil count (ANC) \<500 per cubic millimeter (mm\^3). Grade 4 neutropenia with concurrent invasive infection was defined as infections and infestations (in participants with Grade 4 neutropenia) within 1 week of ANC \<500/mm\^3 and was considered as an AESI (defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).

    Time frame: Baseline up to 60 days

  24. Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation

    Grade \>=2 (moderate) infusion related reactions (defined as any TEAE signs or symptoms experienced by participants who received study medication within 24 hours of the start of infusion) and Grade \>=2 (moderate) hypersensitivity reactions (anaphylactic reaction, hypersensitivity or angioedema and moderate reactions) were considered as AESI which was defined as an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. Gastrointestinal Perforation was defined as formation of a hole through the stomach, large bowel or small intestine.

    Time frame: Baseline up to 60 days

  25. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets

    Criteria for PCSA: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (male) and \<=95 g/L (female); greater than or equal to (\>=) 185 g/L (male) and \>=165 g/L (female); and decrease from baseline \>=20 g/L. * Leukocytes: \<3.0\*10\^9/Liters (L) (Non-Black) or \<2.0\*10\^9/L (black); \>=16.0\*10\^9/L. * Platelets: \< 100\*10\^9/L; \>=700\*10\^9/L.

    Time frame: Baseline up to 60 days

  26. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

    Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L); \>=30% change from baseline; \>= 100% change from baseline.

    Time frame: Baseline up to 60 days

  27. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

    * Alanine Aminotransferase (ALT): \>3 upper limit of normal (ULN); \>5 ULN; \>10 ULN and \>20 ULN. * Bilirubin: \>1.5 ULN; \>2 ULN.

    Time frame: Baseline up to 60 days

07

Results

Posted May 13, 2021

Participant flow

Study was conducted at 46 active centers in 11 countries. A total of 431 participants were screened between 28 March 2020 and 02 July 2020, of which 10 participants were screen failures and 1 participant was randomized twice and thus excluded. Therefore, a total of 420 participants were randomized in the study treatment by the interactive response technology (IRT) (2:2:1 ratio) to receive sarilumab 200 milligrams (mg)/400 mg and placebo. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestoneSarilumab 200 mgSarilumab 400 mgPlacebo
Started16117386
Treated15917384
Participants who received second dose13115
Completed14115375
Not completed202011
Withdrew: Adverse event17189
Withdrew: Other120
Withdrew: Randomized and not treated202

Outcome measures

PrimaryTime to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points

Time to improvement of greater than or equal (\>=) 2 points in clinical status assessment was defined as time (in days) from first dose of study drug to the time of first occurrence of improvement of \>=2 points in clinical status of participants assessed using 7-point ordinal scale (calculated as: Date of first occurrence/episode of the event - date of first dose + 1). Seven-point ordinal scale for clinical assessment ranges from 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score = less severity. Kaplan-Meier method was used for analysis.

Time frame:
Baseline to Day 29
Reported as:
Median · days
Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points10.0 (9.00 to 12.00)10.0 (9.00 to 13.00)12.0 (9.00 to 15.00)
Statistical analysis
  • Sarilumab 200 mg vs Placebo · Log-rank test · p = 0.9561 · Hazard ratio (hr): 1.026 · 95% CI 0.751 to 1.402Hazard ratio for estimation of treatment effect of each sarilumab dose versus placebo was assessed by cox proportional hazard model stratified by severity of illness (severe, critical) and use of systemic corticosteroids (Yes, No) as entered in IRT.
  • Sarilumab 400 mg vs Placebo · Log-rank test · p = 0.3376 · Hazard ratio (hr): 1.135 · 95% CI 0.835 to 1.543Hazard ratio for estimation of treatment effect of each sarilumab dose versus placebo was assessed by cox proportional hazard model stratified by severity of illness (severe, critical) and use of systemic corticosteroids (Yes, No) as entered in IRT.
SecondaryPercentage of Participants Who Were Alive at Day 29

Percentage of participants who were alive at Day 29 were reported in this outcome measure.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Alive at Day 29
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Participants Who Were Alive at Day 2989.991.991.7
Statistical analysis
  • Sarilumab 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6280 · Difference in percentage: -1.7 · 95% CI -9.27 to 5.81By Cochran-Mantel-Haenszel test stratified by severity of illness (severe, critical) and use of systemic corticosteroids (Yes, No) as entered in IRT.
  • Sarilumab 400 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.8478 · Difference in percentage: 0.2 · 95% CI -6.93 to 7.41By Cochran-Mantel-Haenszel test stratified by severity of illness (severe, critical) and use of systemic corticosteroids (Yes, No) as entered in IRT.
SecondaryPercentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29

Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity. Percentage of participants With \>=1 point improvement in clinical status from Baseline at Days 4, 7, 15, 21, and 29 (assessed using the 7-point ordinal scale) were reported.

Time frame:
Baseline, Days 4, 7, 15, 21, and 29
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Day 425.225.423.8
Day 751.648.642.9
Day 1574.876.971.4
Day 2180.581.585.7
Day 2984.984.488.1
SecondaryChange From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score

Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity.

Time frame:
Baseline, Days 4, 7, 15, 21, and 29
Reported as:
Mean · scores on a scale
Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score
scores on a scaleSarilumab 200 mgSarilumab 400 mgPlacebo
Day 40.1 ± 0.90.1 ± 1.00.2 ± 0.9
Day 70.7 ± 1.50.7 ± 1.60.7 ± 1.4
Day 151.9 ± 1.82.0 ± 1.91.7 ± 1.8
Day 212.3 ± 1.92.3 ± 1.92.5 ± 1.7
Day 292.5 ± 1.92.5 ± 1.92.7 ± 1.6
SecondaryTime to Resolution of Fever

Resolution of fever was defined as body temperature less than or equal to (\<=) 36.6 degree Celsius (°C) (axilla), or \<=37.2°C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics/until discharge, whichever was sooner. Time to resolution of fever (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever) - date of first dose + 1. Kaplan-Meier method was used for estimation.

Time frame:
Baseline to Day 29
Reported as:
Median · days
Time to Resolution of Fever
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Time to Resolution of Fever8.0 (7.00 to 9.00)9.0 (7.00 to 10.00)7.0 (6.00 to 12.00)
SecondaryTime to Resolution of Fever and Improvement in Oxygenation

Time to resolution of fever was defined as body temperature \<=36.6°C (axilla), or \<=37.2 °C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, whichever was sooner. Improvement in oxygenation was defined as oxygen saturation (SpO2)/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours, or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to resolution of fever and improvement in oxygenation (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever and improvement in oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.

Time frame:
Baseline to Day 29
Reported as:
Median · days
Time to Resolution of Fever and Improvement in Oxygenation
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Time to Resolution of Fever and Improvement in Oxygenation9.0 (8.00 to 10.00)10.0 (9.00 to 13.00)8.0 (7.00 to 12.00)
SecondaryNumber of Days With Fever

Fever was defined as body temperature greater than (\>) 37.4°C (axilla), or \>38.0 °C (oral), or \>38.4°C (rectal or tympanic) based on maximum value observed during a 24-hour period. Number of days with fever were reported. Least square (LS) mean and standard error (SE) were estimated using the analysis of covariance (ANCOVA) model with treatment group and randomization strata as fixed effects.

Time frame:
Baseline to Day 29
Reported as:
Least squares mean · days
Number of Days With Fever
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Number of Days With Fever1.2 ± 0.231.3 ± 0.211.8 ± 0.30
SecondaryPercentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29

NEWS2: used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. Percentage of participants in following clinical risk categories were reported: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).

Time frame:
Baseline, Days 4, 7, 15, 21, and 29
Reported as:
Number · percentage of participants
Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Baseline: Low28.822.134.2
Baseline: Low to Medium000
Baseline: Medium34.237.427.8
Baseline: High37.040.538.0
Day 4: Low52.856.240.5
Day 4: Low to Medium0.61.20
Day 4: Medium19.516.628.6
Day 4: High27.026.031.0
Day 7: Low57.060.851.4
Day 7: Low to Medium02.10
Day 7: Medium20.010.520.3
Day 7: High23.026.628.4
Day 15: Low52.552.261.1
Day 15: Low to Medium01.52.8
Day 15: Medium21.319.413.9
Day 15: High26.226.922.2
Day 21: Low44.850.066.7
Day 21: Low to Medium13.800
Day 21: Medium24.121.18.3
Day 21: High17.228.925.0
Day 29: Low57.127.860.0
Day 29: Low to Medium000
Day 29: Medium14.327.820.0
Day 29: High28.644.420.0
SecondaryTime to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours

Time to NEWS2 \<2 and maintained for 24 hours: time (in days) from 1st dose of study drug until 1st occurrence of NEWS score of \<2 (maintained for 24 hours); calculated as: date of 1st occurrence/episode of event (NEWS score of \<2) - date of 1st dose + 1. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (score of 0 or 1 was allocated) and level of consciousness (score of 0 or 3 was allocated), where 0=normal health condition to 3=worst health condition; higher score=more severity. All scores were summed to get an aggregate score which ranged from 0 to 19, with higher scores=more severity/higher risk. Kaplan-Meier method was used for analysis.

Time frame:
Baseline to Day 29
Reported as:
Median · days
Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours9.0 (7.00 to 10.00)9.0 (8.00 to 11.00)11.0 (8.00 to 14.00)
SecondaryChange From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2

The NEWS2 was used to standardize the assessment of acute-illness severity, track the clinical condition of participants, and to alert clinical teams to participant deterioration. NEWS2 score is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. LS means and SE were estimated using ANCOVA model with treatment group and randomization strata as fixed effects, and baseline NEWS2 score as a covariate.

Time frame:
Baseline, Days 4, 7, 15, 21, and 29
Reported as:
Least squares mean · scores on a scale
Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2
scores on a scaleSarilumab 200 mgSarilumab 400 mgPlacebo
Day 4-1.07 ± 0.212-1.25 ± 0.198-0.36 ± 0.274
Day 7-1.63 ± 0.265-1.47 ± 0.245-0.83 ± 0.338
Day 15-2.10 ± 0.508-1.83 ± 0.467-2.36 ± 0.641
Day 21-3.02 ± 0.769-2.24 ± 0.676-2.96 ± 1.090
Day 29-2.57 ± 0.936-1.27 ± 0.884-3.64 ± 1.508
SecondaryTime-to-improvement in Oxygenation

Time-to-improvement in oxygenation was defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to improvement in oxygenation was calculated as: date of first occurrence/episode of the event (oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.

Time frame:
Baseline to Day 29
Reported as:
Median · days
Time-to-improvement in Oxygenation
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Time-to-improvement in Oxygenation6.0 (5.00 to 7.00)6.0 (5.00 to 7.00)7.0 (5.00 to 8.00)
SecondaryPercentage of Participants Alive Off Supplemental Oxygen at Day 29

Supplemental oxygen was defined as oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Alive Off Supplemental Oxygen at Day 29
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Participants Alive Off Supplemental Oxygen at Day 2984.983.886.9
SecondaryPercentage of Days With Hypoxemia

Hypoxemia (low level of oxygen in the blood) was defined as SpO2 \<93% on room air, or required supplemental oxygen, or mechanical ventilatory support. Days meeting the criteria for hypoxemia since the first study dose were counted and the percentage of days with hypoxemia were calculated as:100\*number of days with the hypoxemia divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

Time frame:
Baseline to Day 29
Reported as:
Least squares mean · percentage of days
Percentage of Days With Hypoxemia
percentage of daysSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Days With Hypoxemia73.01 ± 2.06375.10 ± 1.94176.32 ± 2.724
SecondaryPercentage of Days With Supplemental Oxygen Use

Supplemental oxygen (oxygen therapy) was defined as oxygen administration using oxygen delivery device (e.g. nasal cannula, simple face mask, non-rebreather mask, high flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, extracorporeal life support, etc.). Days meeting the criteria for supplemental oxygen use since the first study dose were counted and the percentage of days with supplemental oxygen use were calculated as:100\*number of days with the supplemental oxygen use divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29) . LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

Time frame:
Baseline to Day 29
Reported as:
Least squares mean · percentage of days
Percentage of Days With Supplemental Oxygen Use
percentage of daysSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Days With Supplemental Oxygen Use70.57 ± 2.08273.30 ± 1.95973.23 ± 2.748
SecondaryPercentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute

Resting respiratory rate was measured in terms of number of breaths per minute (bpm) while a person is at rest. Only the days with respiratory rate \>24 breath per minute since the first dose were counted and percentage of days with respiratory rate \> 24 bpm were calculated as:100\*number of days with respiratory rate \>24 bpm divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

Time frame:
Baseline to Day 29
Reported as:
Least squares mean · percentage of days
Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute
percentage of daysSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute14.74 ± 1.58214.58 ± 1.48515.74 ± 2.105
SecondaryTime to Oxygen Saturation >= 94% on Room Air

Time to oxygen saturation \>=94% on room air was defined as the time (in days) from first dose of study drug until the time of first occurrence of oxygen saturation \>=94% and it was calculated as: Date of first occurrence/episode of the event (oxygen saturation \>=94%) - date of first dose + 1.Kaplan-Meier method was used for estimation.

Time frame:
Baseline to Day 29
Reported as:
Median · days
Time to Oxygen Saturation >= 94% on Room Air
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Time to Oxygen Saturation >= 94% on Room Air8.0 (6.00 to 10.00)8.0 (8.00 to 11.00)8.0 (7.00 to 11.00)
SecondaryMean Number of Ventilator Free Days

Mean number of ventilator free days in participants were reported.

Time frame:
Baseline to Day 29
Reported as:
Mean · days
Mean Number of Ventilator Free Days
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Mean Number of Ventilator Free Days23.8 ± 9.424.0 ± 8.824.9 ± 8.6
SecondaryPercentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula

Percentage of participants With initiation of mechanical ventilation or non-invasive ventilation, or use of high flow nasal cannula were reported in this outcome measure.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula20.523.419.1
SecondaryPercentage of Participants Who Required Rescue Medication

Rescue medications were defined as the immunosuppressive (methylprednisolone, dexamethasone and prednisone) therapies. During the course of the study, participant who required rescue therapy was based on the judgement of the study physician.

Time frame:
Baseline to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Rescue Medication
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Participants Who Required Rescue Medication13.815.022.6
SecondaryPercentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study

Percentage of participants who needed ICU care until Day 29 were reported for those not in an ICU at baseline.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study
percentage of participantsSarilumab 200 mgSarilumab 400 mgPlacebo
Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study11.214.912.5
SecondaryNumber of Days of Hospitalization Among Survivors (Alive Participants)

Number of days of hospitalization among alive participants were counted at Day 60 since the first dose. LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.

Time frame:
At Day 60
Reported as:
Least squares mean · days
Number of Days of Hospitalization Among Survivors (Alive Participants)
daysSarilumab 200 mgSarilumab 400 mgPlacebo
Number of Days of Hospitalization Among Survivors (Alive Participants)15.6 ± 0.9616.1 ± 0.9115.9 ± 1.27
SecondaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Treatment-emergent AEs (TEAEs) were the AEs that developed or worsened or became serious during the TEAE period (from the time of first dose of study drug to the last dose of study drug + 60 days). SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)425120
SecondaryNumber of Participants With Major or Opportunistic Bacterial or Fungal Infections

Major or opportunistic bacterial or fungal infections was considered as an adverse event of special interest (AESI: defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Major or Opportunistic Bacterial or Fungal Infections
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
Number of Participants With Major or Opportunistic Bacterial or Fungal Infections8153
SecondaryNumber of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection

Grade 4 neutropenia was defined as participants with absolute neutrophil count (ANC) \<500 per cubic millimeter (mm\^3). Grade 4 neutropenia with concurrent invasive infection was defined as infections and infestations (in participants with Grade 4 neutropenia) within 1 week of ANC \<500/mm\^3 and was considered as an AESI (defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
Grade 4 neutropenia360
Grade 4 neutropenia with concurrent invasive infection00—
SecondaryNumber of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation

Grade \>=2 (moderate) infusion related reactions (defined as any TEAE signs or symptoms experienced by participants who received study medication within 24 hours of the start of infusion) and Grade \>=2 (moderate) hypersensitivity reactions (anaphylactic reaction, hypersensitivity or angioedema and moderate reactions) were considered as AESI which was defined as an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. Gastrointestinal Perforation was defined as formation of a hole through the stomach, large bowel or small intestine.

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
Grade >=2 Infusion related reactions160
Grade >=2 Hypersensitivity reactions170
Gastrointestinal perforation100
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets

Criteria for PCSA: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (male) and \<=95 g/L (female); greater than or equal to (\>=) 185 g/L (male) and \>=165 g/L (female); and decrease from baseline \>=20 g/L. * Leukocytes: \<3.0\*10\^9/Liters (L) (Non-Black) or \<2.0\*10\^9/L (black); \>=16.0\*10\^9/L. * Platelets: \< 100\*10\^9/L; \>=700\*10\^9/L.

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
Hemoglobin <=115 g/L (male) and <=95 g/L (female)293415
Hemoglobin >=185 g/L (male) and >=165 g/L (female)000
Hemoglobin decrease from baseline >=20 g/L323015
Leukocytes <3.0*10^9/L (Non-Black) or <2.0*10^9/L (black)19311
Leukocytes >=16*10^9/L13216
Platelets <100*10^9/L273
Platelets >=700*10^9/L322
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L); \>=30% change from baseline; \>= 100% change from baseline.

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
Creatinine >=150 mcmol/L15155
>=30% change from baseline in Creatinine313010
>=100% change from baseline in Creatinine673
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

* Alanine Aminotransferase (ALT): \>3 upper limit of normal (ULN); \>5 ULN; \>10 ULN and \>20 ULN. * Bilirubin: \>1.5 ULN; \>2 ULN.

Time frame:
Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
ParticipantsSarilumab 200 mgSarilumab 400 mgPlacebo
ALT >3 ULN606324
ALT >5 ULN282512
ALT >10 ULN653
ALT >20 ULN100
Bilirubin >1.5 ULN544
Bilirubin >2 ULN422

Adverse events

Collected over All AEs were collected from the time of first dose of study drug up to 60 days regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab 200 mg17/159 (10.7%)42/159 (26.4%)57/159 (35.8%)
Sarilumab 400 mg18/173 (10.4%)51/173 (29.5%)68/173 (39.3%)
Placebo9/84 (10.7%)20/84 (23.8%)14/84 (16.7%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventSarilumab 200 mgSarilumab 400 mgPlacebo
Covid-19 PneumoniaInfections and infestations11/1594/1732/84
Respiratory FailureRespiratory, thoracic and mediastinal disorders6/1595/1733/84
Atrial FibrillationCardiac disorders0/1590/1733/84
Multiple Organ Dysfunction SyndromeGeneral disorders2/1593/1733/84
PneumoniaInfections and infestations1/1596/1730/84
Septic ShockInfections and infestations4/1594/1732/84
Alanine Aminotransferase IncreasedInvestigations4/1593/1731/84
Bacterial InfectionInfections and infestations0/1591/1732/84
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/1592/1732/84
Acute Kidney InjuryRenal and urinary disorders2/1594/1730/84
Most frequent other events
Most frequent other events
EventSarilumab 200 mgSarilumab 400 mgPlacebo
Alanine Aminotransferase IncreasedInvestigations48/15958/17314/84
Aspartate Aminotransferase IncreasedInvestigations11/15915/1730/84
NeutropeniaBlood and lymphatic system disorders11/15913/1730/84

Baseline characteristics

Analysis was performed on randomized population.

Age, Continuous
Age, Continuous(years)Sarilumab 200 mgSarilumab 400 mgPlaceboTotal
Mean58.3 ± 13.758.0 ± 14.159.9 ± 14.858.5 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab 200 mgSarilumab 400 mgPlaceboTotal
Female527430156
Male1099956264
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sarilumab 200 mgSarilumab 400 mgPlaceboTotal
American Indian or Alaska Native2215
Asian59620
Native Hawaiian or Other Pacific Islander0011
Black or African American3519
White12812869325
More than one race0303
Unknown or Not Reported2326857
Clinical Status: 7-point ordinal scale
Clinical Status: 7-point ordinal scale(Participants)Sarilumab 200 mgSarilumab 400 mgPlaceboTotal
Scale Score 10000
Scale Score 217241051
Scale Score 328211160
Scale Score 411312865306
Scale Score 53003
Scale Score 60000
Scale Score 70000
08

Study locations

47 sites
  • Investigational Site Number 0320001
    Caba, 1430, Argentina
  • Investigational Site Number 0320003
    Caba, C1180AAX, Argentina
  • Investigational Site Number 0320004
    Caba, C1426AAM, Argentina
  • Investigational Site Number 0760003
    Porto Alegre, 90110-270, Brazil
  • Investigational Site Number 0760004
    São José do Rio Preto, 15090-000, Brazil
  • Investigational Site Number 0760001
    São Paulo, 01327-001, Brazil
  • Investigational Site Number 0760002
    São Paulo, 04231-030, Brazil
  • Investigational Site Number 0760005
    São Paulo, 04321-120, Brazil
  • Investigational Site Number 1240001
    Montreal, H2X3E4, Canada
  • Investigational Site Number 1240005
    Montreal, H4A 3J1, Canada
  • Investigational Site Number 1240004
    Toronto, M4N3M5, Canada
  • Investigational Site Number 1240002
    Toronto, M5G 2N2, Canada
  • Investigational Site Number 1240003
    Vancouver, V5Z 1M9, Canada
  • Investigational Site Number 1520003
    Santiago, 750-0691, Chile
  • Investigational Site Number 1520002
    Santiago, 80004005, Chile
  • Investigational Site Number 1520004
    Santiago, Chile
  • Investigational Site Number 1520001
    Talca, 3460001, Chile
  • Investigational Site Number 2500001
    Bordeaux, 33076, France
  • Investigational Site Number 2500007
    Clamart, 92140, France
  • Investigational Site Number 2500006
    La Roche-sur-Yon, 85925, France
  • Investigational Site Number 2500002
    Nantes, 44093, France
  • Investigational Site Number 2500005
    Paris, 75877, France
  • Investigational Site Number 2500003
    Strasbourg, 67098, France
  • Investigational Site Number 2500004
    Suresnes, 92151, France
  • Investigational Site Number 2760004
    Cologne, 50937, Germany
  • Investigational Site Number 2760002
    Essen, 45147, Germany
  • Investigational Site Number 2760001
    Münster, 48149, Germany
  • Investigational site number 3760003
    Ashdod, 7747629, Israel
  • Investigational Site Number 3760002
    Jerusalem, 91120, Israel
  • Investigational Site Number 3760001
    Ramat Gan, 52662, Israel
  • Investigational Site Number 3800005
    Milan, 20122, Italy
  • Investigational Site Number 3800001
    Milan, 20132, Italy
  • Investigational Site Number 3800002
    Milan, 20157, Italy
  • Investigational Site Number 3800003
    Modena, 41100, Italy
  • Investigational Site Number 3800004
    Parma, 43100, Italy
  • Investigational Site Number 3800006
    Rozzano, 20089, Italy
  • Investigational Site Number 3920002
    Fuchu-Shi, Japan
  • Investigational Site Number 3920003
    Iruma-Gun, Japan
  • Investigational Site Number 3920001
    Kamakura-Shi, Japan
  • Investigational Site Number 6430003
    Moscow, 111539, Russia
  • Investigational Site Number 6430002
    Moscow, 123182, Russia
  • Investigational Site Number 6430001
    Moscow, 129301, Russia
  • Investigational Site Number 7240003
    Barcelona, 08035, Spain
  • Investigational Site Number 7240004
    Barcelona, 08036, Spain
  • Investigational Site Number 7240002
    Madrid, 28007, Spain
  • Investigational Site Number 7240005
    Madrid, 28034, Spain
  • Investigational Site Number 7240001
    Madrid, 28046, Spain
09

References and documents

Publications

  • Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O; Sarilumab COVID-19 Global Study Group. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 May;9(5):522-532. doi: 10.1016/S2213-2600(21)00099-0. Epub 2021 Mar 4. PubMed 33676590 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jul 2020, 4 months.

Results were first posted in May 2021, 9 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Coronavirus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 25. This study's 4 months is below that.

Counting every sponsor, half of 91 studies reached it within 11 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 31, 2020
StartActual
Mar 28, 2020
Primary completionActual
Jul 31, 2020
CompletionActual
Sep 2, 2020
Results first posted
May 13, 2021
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04327388
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Mar 28, 2020
Primary completion
Jul 31, 2020
Completion
Sep 2, 2020
Results posted
May 13, 2021
Last update
Sep 24, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion